Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Niagen Bioscience Inc (NAGE)
USD3.53
+0.24 (+7.14%)
US NASDAQ Healthcare Biotechnology
Address
10900 Wilshire Blvd, Suite 600 90024
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Robert N. Fried
Website
niagenbioscience.com
IPO
2015-06-24
CIK 1386570 ISIN US1710774076
Also trades on
NASDAQ Capital Market · CDXC (USD)
NASDAQ Capital Market · NAGE (USD)
Description
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
News Sentiment (7d)
4 articles
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases Business Wire
- Implied Volatility Surging for Niagen Bioscience Stock Options Zacks Investment Research
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026 GuruFocus
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.53
+0.24 (+7.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
833.3K
Beta
2.06
Float Shares
52.63M
Free Float %
66.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.48% | -14.72% | -7.33% | -18.55% | -41.27% | -34.43% | -55.59% | +183.67% | -41.76% | -11.28% | -64.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
3.53
Low
10.00
+183.7%
Consensus
10.00
+183.7%
Median
10.00
+183.7%
High
10.00
+183.7%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
10.00
+183.7%
|
| Last Quarter | 1 |
10.00
+183.7%
|
| Last Year | 2 |
12.00
+240.4%
|
| All Time | 2 |
12.00
+240.4%
|
Quality scores
Altman Z-Score
6.63
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+30.0% ★ Q1'26: +3.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+81.8% ★ Q1'26: +22.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+4.9% Q1'26: -4.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+11.1% ★ Q1'26: +5.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+93.8% ★ Q1'26: +32.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.2% Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.18× ★ Q1'26: 0.34× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.66M
est: 26.77M (-19.1%)
|
21.20M
est: 23.34M (-9.1%)
|
31.56M
est: 31.63M (-0.2%)
|
46.29M
est: 46.17M (+0.3%)
|
59.26M
est: 59.16M (+0.2%)
|
67.45M
est: 68.33M (-1.3%)
|
72.05M
est: 72.34M (-0.4%)
|
83.57M
est: 83.20M (+0.4%)
|
99.60M
est: 97.19M (+2.5%)
|
129.42M
est: 127.29M (+1.7%)
|
142.63M
139.46M – 145.78M
+12.1% YoY
|
167.65M
162.23M – 173.08M
+17.5% YoY
|
203.40M
198.88M – 207.88M
+21.3% YoY
|
| EBITDA |
-2.49M
est: -4.68M (+46.8%)
|
-15.66M
est: -4.08M (-284.2%)
|
-32.33M
est: -5.53M (-485.1%)
|
-29.78M
est: -8.06M (-269.3%)
|
-18.34M
est: -10.33M (-77.5%)
|
-25.45M
est: -11.93M (-113.2%)
|
-16.74M
est: -12.63M (-32.5%)
|
-3.89M
est: -14.53M (+73.2%)
|
9.21M
est: -8.59M (+207.2%)
|
15.75M
est: -11.26M (+239.9%)
|
-12.61M
-12.89M – -12.33M
-12.1% YoY
|
-14.82M
-15.30M – -14.35M
-17.5% YoY
|
-17.99M
-18.38M – -17.59M
-21.3% YoY
|
| EBIT |
-2.91M
est: -5.27M (+44.9%)
|
-16.38M
est: -4.59M (-256.5%)
|
-33.17M
est: -6.23M (-432.6%)
|
-31.30M
est: -9.09M (-244.3%)
|
-19.85M
est: -11.65M (-70.4%)
|
-27.07M
est: -13.45M (-101.2%)
|
-18.63M
est: -14.24M (-30.8%)
|
-5.60M
est: -16.38M (+65.8%)
|
7.73M
est: -10.48M (+173.8%)
|
14.30M
est: -13.72M (+204.2%)
|
-15.37M
-15.71M – -15.03M
-12.1% YoY
|
-18.07M
-18.65M – -17.48M
-17.5% YoY
|
-21.92M
-22.41M – -21.44M
-21.3% YoY
|
| Net Income |
-2.93M
est: -2.39M (-22.4%)
|
-11.38M
est: -29.90M (+61.9%)
|
-33.32M
est: -47.04M (+29.2%)
|
-32.15M
est: -41.14M (+21.9%)
|
-19.93M
est: -25.31M (+21.3%)
|
-27.13M
est: -34.05M (+20.3%)
|
-16.54M
est: -19.93M (+17.0%)
|
-4.94M
est: -7.18M (+31.2%)
|
8.55M
est: 3.42M (+150.2%)
|
17.38M
est: 15.55M (+11.8%)
|
21.63M
16.05M – 29.42M
+39.1% YoY
|
28.74M
21.89M – 32.40M
+32.9% YoY
|
35.88M
35.51M – 36.25M
+24.9% YoY
|
| SGA |
10.77M
est: 19.88M (-45.8%)
|
22.10M
est: 17.33M (+27.5%)
|
43.67M
est: 23.50M (+85.9%)
|
52.52M
est: 34.29M (+53.2%)
|
51.71M
est: 43.94M (+17.7%)
|
64.73M
est: 50.75M (+27.5%)
|
56.60M
est: 53.73M (+5.3%)
|
51.42M
est: 61.79M (-16.8%)
|
47.84M
est: 64.62M (-26.0%)
|
62.56M
est: 84.63M (-26.1%)
|
94.83M
92.73M – 96.92M
+12.1% YoY
|
111.47M
107.86M – 115.07M
+17.5% YoY
|
135.23M
132.23M – 138.21M
+21.3% YoY
|
| EPS |
-0.08
est: -0.03 (-161.7%)
|
-0.26
est: -0.38 (+30.7%)
|
-0.61
est: -0.59 (-3.4%)
|
-0.56
est: -0.52 (-8.5%)
|
-0.33
est: -0.32 (-3.9%)
|
-0.40
est: -0.43 (+6.3%)
|
-0.24
est: -0.25 (+4.0%)
|
-0.07
est: -0.09 (+22.2%)
|
0.10
est: 0.04 (+150.0%)
|
0.22
est: 0.18 (+20.9%)
|
0.24
0.19 – 0.34
+31.9% YoY
|
0.31
0.26 – 0.38
+28.1% YoY
|
0.42
0.42 – 0.42
+36.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Canaccord Genuity | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
5.43M
OE per share TTM
0.06
Owner's Yield
1.63%
Maintenance CapEx ratio
0.00%
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
1
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Gabelli Love Our Planet & People ETF LOPP | 0.45% | 81.8K | 0.90% |
| 2 | Amplify Etho Climate Leadership U.S. ETF ETHO | 0.22% | 418.7K | 0.45% |
| 3 | Vanguard U.S. Quality Factor ETF VFQY | 0.09% | 413.0K | 0.13% |
| 4 | Vanguard Consumer Staples ETF VDC | 0.03% | 2.32M | 0.09% |
| 5 | U.S. Small Cap Growth Portfolio: ETF Class Shares DUSG | 0.01% | 287.1K | 0.33% |
| 6 | Vanguard Russell 2000 Growth ETF VTWG | 0.01% | 192.2K | 0.06% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.01% | 91.7K | 0.08% |
| 8 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 33.6K | 0.36% |
| 9 | Principal U.S. Small-Cap Multi-Factor ETF PSC | 0.01% | 78.0K | 0.38% |
| 10 | Vanguard Russell 2000 ETF VTWO | 0.01% | 1.02M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
7.00
Bullish
Ratio by volume
2.80
Bullish
Buys
7
Sells
1
Shares acquired
186.7K
Shares disposed
66.7K
Cash buys
—
Cash sales
—
Net activity
+120,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | Fried Robert N | Director / Officer | M-Exempt | D | Stock Options (right to buy) | 20,000 | 2.61 | 52.2K | 0 | D | ↗ |
| 2026-02-19 | Pamir Ozan | Officer | A-Award | A | Employee Stock Options (right to buy) | 62,131 | 4.94 | 306.9K | 62,131 | D | ↗ |
| 2026-02-19 | Lopez Carlos Luis | Officer | A-Award | A | Employee Stock Options (right to buy) | 41,420 | 4.94 | 204.6K | 41,420 | D | ↗ |
| 2026-02-19 | Fried Robert N | Director / Officer | A-Award | A | Employee Stock Options (right to buy) | 503,937 | 4.94 | 2.49M | 503,937 | D | ↗ |
| 2025-11-14 | Pamir Ozan | Officer | P-Purchase | A | Common Stock | 2,220 | 6.85 | 15.2K | 2,220 | I | ↗ |
| 2025-06-24 | YU Wing Tak Wendy | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Shahbazi Hamed | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Rubin Steven D | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Patrick Kristin | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Ng Wang Yu Gary | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Jaksch Frank L Jr | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-06-24 | Cohen Ann | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 14.13 | 282.6K | 20,000 | D | ↗ |
| 2025-04-09 | Fried Robert N | Director / Officer | M-Exempt | D | Stock Options (right to buy) | 66,667 | 3.30 | 220.0K | 0 | D | ↗ |
Executive team
Top executives
EBIT / Employee
137.5K
Shares Outstanding
79.64M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert N. Fried | Chief Executive Officer & Director | 1M | male |
| Ozan Pamir | Chief Financial Officer & Principal Accounting Officer | 648.2K | male |
| Carlos Lopez | Senior Vice President & General Counsel | 480.0K | male |
| James Lee | Controller | 286.5K | male |
| Frank Louis Jaksch Jr. | Co-Founder & Chairman | 70.0K | male |
| Andrew Shao | Senior Vice President of Global Regulatory & Scientific Affairs | — | — |
| Wesley Yu | Vice President of Finance | — | — |
| Chu Yan | Managing Director of Asia Pacific | — | female |
| Kendall Knysch | Head of Media Relations & Partnerships | — | — |
| Lauren Rittman-Borzansky | Assistant Controller | — | female |
| Michiko Kelley | Chief Marketing Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NAGE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
